What is the clinical evidence from this study?

Study design: null. Population: pancreatic cancer. Intervention: null vs. null. Primary outcome: null (null, 95% CI null, p=null).

What does this research mean for the field?

Aberrant de novo lipid synthesis and reprogrammed lipid metabolism drive the development and progression of pancreatic cancer, presenting viable targets for novel individualized therapies. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to summarize the role of lipid metabolism and lipid droplets in pancreatic ductal adenocarcinoma (PDAC).

March 13, 2026Open Access

Lipid metabolism and lipid droplets in pancreatic cancer and stellate cells

Key Result

null

Key Points

The aim is to summarize the role of lipid metabolism and lipid droplets in pancreatic ductal adenocarcinoma (PDAC).
Reviewed molecular mechanisms of lipid metabolism in pancreatic cancer
Examined roles of relevant enzymes in lipid metabolism
Summarized preclinical studies and clinical trials targeting cancer metabolic systems
Lipid metabolism reprogramming is associated with pancreatic cancer development
Enzymes involved in lipid metabolism play significant roles in PDAC
Understanding lipid metabolism may aid in developing personalized therapies for pancreatic cancer

Study Design

Type

null

Blinding

null

Randomization

null

Multicenter

PICO

Population

pancreatic cancer

Intervention / Comparator

null vs null (null)

Primary Outcome

null — null (null), p=null

Main Result

Effect estimate: null (95% CI null)

p-value: p=null

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer by 2030, and the overall 5-year survival rate is currently less than 7%. Cancer cells frequently exhibit reprogramming of their metabolic activity. It is increasingly recognized that aberrant de novo lipid synthesis and reprogrammed lipid metabolism are both associated with the development and progression of various cancers, including pancreatic cancer. In this review, the current knowledge about lipid metabolism and lipid droplets in pancreatic cancer is discussed. In the first part, molecular mechanisms of lipid metabolism and roles of enzymes involved in lipid metabolism which are relevant for pancreatic cancer research are presented. Further, preclinical studies and clinical trials with drugs/inhibitors targeting cancer metabolic systems in cancer are summarized. An increase of our knowledge in lipid metabolism in pancreatic cancer cells and in tumor stroma is important for developing novel strategies of future individualized therapies of pancreatic cancer.

Bookmark

View Full Paper

Cite This Study

Sunami et al. (Mon,) conducted a null in pancreatic cancer. null vs. null was evaluated on null (null, 95% CI null, p=null). null.

synapsesocial.com/papers/69b3abc502a1e69014ccceae https://doi.org/https://doi.org/10.25673/122564

Bookmark

View Full Paper